Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884 | Completed Phase 2 FDA Drug

• 2 other identifiers: ML43601164104
• Study Type: interventional
• Target: 179
• Locations: 1 country
• Sites: 16

Brief Summary

The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.

Conditions

Non-Proliferative Diabetic Retinopathy

Outcome Measures

Primary Outcomes (2)

• Primary Objective

  Analyze the change in the area of retinal non-perfusion (RNP) within the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR.

  48 weeks

• Primary Objective

  Analyze the change in the area of retinal non-perfusion (RNP) outside the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR.

  48 weeks

Secondary Outcomes (9)

• Change in area of RNP

  Baseline through week 96

• Change in area of RNP within the macula

  Baseline through week 48 and from baseline through week 96

• Change in area of RNP outside of the macula

  Baseline through week 48 and from baseline through week 96

• Percentage of subjects with disease

  Baseline through week 96

• Mean change in ETDRS

  Baseline through week 48 and from baseline through week 96

Study Arms (2)

Group 1

EXPERIMENTAL

Subjects will be administered intravitreal faricimab 6 mg every 4 weeks (defined as every 28 days + 7 days and at least 21 days between injections) through week 48. Starting at Week 48, subjects will be treated every 16 weeks (weeks 48, 64 \& 80) with an end of study visit at week 96. Rescue: At any visit after Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial.

Drug: Faricimab

Group 2

EXPERIMENTAL

Subjects are seen and observed every 16 weeks. Starting at Week 48, subjects will be administered intravitreal faricimab 6 mg every 4 weeks from week 48 to week 92, (defined as every 28 days ± 7 days and at least 21 days between injections) with an end of study visit at week 96. Rescue: At any visit before Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial.

Drug: Faricimab

Interventions

Faricimab DRUG

Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide signed IRB-approved informed consent form (ICF) prior to any study-specific procedures
• Willing and able to comply with clinic visits and study-related procedures and likely to return for all study visits, in the investigator's judgement
• Men or women \> 18 years of age at the time of signing the Informed Consent Form
• Diagnosis of diabetes mellitus (type 1 or type 2)
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the final dose of study treatment. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a post-menopausal state (\>12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. Examples of acceptable contraceptive methods include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
• Contraception methods that do not result in a failure rate of \< 1% per year such as male or female condom with or without spermicide; and cap, diaphragm, or sponge with spermicide are not acceptable.
• The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. If a subject is usually not sexually active but becomes active, they, with their partner, must comply with the contraceptive requirements of the study.
• ETDRS BCVA \> 20/400 in the study eye
• Non-proliferative diabetic retinopathy, as confirmed by the site investigator
• Substantial non-perfusion (defined as greater than 5 disc areas on Wide-Field Fluorescein Angiograph (WFFA)), as assessed by site investigator

You may not qualify if:

• Any known hypersensitivity to any of the components in the faricimab injection
• Any known hypersensitivity to any contrast media (e.g., fluorescein), dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used by the site during the study
• Active cancer within the past 12 months prior to Screen/Baseline except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for \>12 months
• Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Screen/Baseline
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
• o Women of childbearing potential must have a negative urine pregnancy test at the Screen/Baseline visit for both Group 1 and Group 2. Women of childbearing potential must also have a negative urine pregnancy test on any visit where they will receive treatment with IP or rescue medication. Urine pregnancy tests must be completed prior to the administration of IP/rescue medication and prior to FA being performed.
• Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins or minerals) within 3 months (or 5 half-lives, whichever is longer) prior to Screen/Baseline, or during the course of this study
• Any prior or concomitant systemic anti-VEGF treatment within 4 months prior to Screen/Baseline
• Any use of any prohibited therapies during times of prohibition.
• Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye within 4 months prior to Screen/Baseline
• SD-OCT central subfield thickness (CST) measurement \> 325 µm, in the study eye due to DME.
• Evidence of infectious ocular infection, in the study eye at Screen/Baseline
• Any pan-retinal photocoagulation (PRP) treatment received in the study eye prior to Screen/Baseline
• Retinal vein occlusion in the study eye
• Cystoid macular edema not attributed to diabetes (instead caused by epiretinal membrane, macular telangiectasia, Coats disease, and inherited retinal diseases) in the study eye

Sponsors & Collaborators

• Greater Houston Retina Research: lead
• Genentech, Inc.: collaborator

Study Sites (16)

California Retina Consultants

Bakersfield, California, 93309, United States

Location

Retinal Consultants Medical Group

Modesto, California, 95356, United States

Location

Florida Retina Institute

Orlando, Florida, 32806, United States

Location

Retina Group of Florida

Sarasota, Florida, 34233, United States

Location

Retina Consultants of Minnesota St. Louis Park

Saint Louis Park, Minnesota, 55416, United States

Location

Mississippi Retina Associates

Jackson, Mississippi, 39202, United States

Location

Long Island Vitreoretinal Consultants

Westbury, New York, 11590, United States

Location

North Carolina Retina Associates

Wake Forest, North Carolina, 27587, United States

Location

Charleston Neuroscience Institute

Ladson, South Carolina, 29456, United States

Location

Palmetto Retina Center

West Columbia, South Carolina, 29169, United States

Location

Austin Retina Associates

Austin, Texas, 78705, United States

Location

Retina Consultants of Texas

Beaumont, Texas, 77707, United States

Location

Retina Consultants of Texas

Bellaire, Texas, 77401, United States

Location

Retina Consultants of Texas

Katy, Texas, 77494, United States

Location

Retina Consultants of Texas

San Antonio, Texas, 78240, United States

Location

Retina Consultants of Texas

The Woodlands, Texas, 77384, United States

Location

Related Publications (1)

• Zhou AW, Sahraravand RA, Baumann LM, Teagle GM, Brown J, Pieramici D, Holy SE, Borne MJ, Wong RW, Cunningham MA, Pearce WA, Rahman EZ, Chang M, Bhavsar AR, Brown DM, Alfaro DV, Fan KC, Cehofski LJ, Ip M, Sadda SR, Lesmes LA, Ehlers JP, Chaudhary V, Al-Khersan H, Wykoff CC. MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Ophthalmologica. 2026 Jan 26:1-10. doi: 10.1159/000550491. Online ahead of print.

  PMID: 41587134 DERIVED

MeSH Terms

Interventions

faricimab

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Randomized during the enrollment phase of the study in a 1:1 ratio to one of two treatment arms.

Study Record Dates

• First Submitted: November 4, 2022
• First Posted: January 12, 2023
• Study Start: May 16, 2023
• Primary Completion: February 26, 2026
• Study Completion: February 26, 2026
• Last Updated: March 20, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (16)